JPH0456804B2 - - Google Patents
Info
- Publication number
- JPH0456804B2 JPH0456804B2 JP59049321A JP4932184A JPH0456804B2 JP H0456804 B2 JPH0456804 B2 JP H0456804B2 JP 59049321 A JP59049321 A JP 59049321A JP 4932184 A JP4932184 A JP 4932184A JP H0456804 B2 JPH0456804 B2 JP H0456804B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- virus
- 20mer
- rna
- messenger rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 35
- 108020004999 messenger RNA Proteins 0.000 claims description 33
- 239000003443 antiviral agent Substances 0.000 claims description 27
- 230000036961 partial effect Effects 0.000 claims description 8
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 62
- 241000700605 Viruses Species 0.000 description 42
- 239000000243 solution Substances 0.000 description 25
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 22
- 241000700584 Simplexvirus Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 12
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 11
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 11
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 9
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 108020004682 Single-Stranded DNA Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000001243 protein synthesis Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 241001524679 Escherichia virus M13 Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000005727 virus proliferation Effects 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108010039177 polyphenylalanine Proteins 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 108700002232 Immediate-Early Genes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710149086 Nuclease S1 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 101150076514 NS gene Proteins 0.000 description 2
- 101150033828 NS1 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 For example Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- SBYQPGZCKZIXFK-UHNVWZDZSA-N CC(C)(O)[C@@H](S)[C@H](O)CO Chemical compound CC(C)(O)[C@@H](S)[C@H](O)CO SBYQPGZCKZIXFK-UHNVWZDZSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000890148 Jerseyvirus Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- VOAXAOULFRTTAM-UHFFFAOYSA-N chloroform phenol Chemical compound C1(=CC=CC=C1)O.C(Cl)(Cl)Cl.C1(=CC=CC=C1)O.C1(=CC=CC=C1)O VOAXAOULFRTTAM-UHFFFAOYSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59049321A JPS60193922A (ja) | 1984-03-16 | 1984-03-16 | 抗ウイルス剤 |
| NZ209840A NZ209840A (en) | 1983-10-17 | 1984-10-10 | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
| GB08425799A GB2148302B (en) | 1983-10-17 | 1984-10-12 | Method for inhibiting viral propagation and anti-viral agent |
| AU34239/84A AU578625B2 (en) | 1983-10-17 | 1984-10-15 | Method for inhibiting propagation of virus and anti-viral agent |
| LU85594A LU85594A1 (de) | 1983-10-17 | 1984-10-15 | Oligodeoxynucleotide und polydeoxynucleotide,die mit einem bereich einer bei der virusvermehrung synthetisierten mrna hybridisieren und ihre anwendung als therapeutische wirkstoffe |
| SE8405133A SE466482B (sv) | 1983-10-17 | 1984-10-15 | Med mrna hybridiserbart antiviralt medel |
| US06/661,204 US4689320A (en) | 1983-10-17 | 1984-10-15 | Method for inhibiting propagation of virus and anti-viral agent |
| PH31340A PH21629A (en) | 1983-10-17 | 1984-10-15 | Method for inhibiting propagation of virus and anti-viral agent |
| AT0329284A AT392081B (de) | 1983-10-17 | 1984-10-16 | Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen |
| DK493584A DK168061B1 (da) | 1983-10-17 | 1984-10-16 | Med mrna hybridiserbart anti-viralt middel |
| IT68021/84A IT1179144B (it) | 1983-10-17 | 1984-10-16 | Agente anti virale e procedimento per inibire la propagazione di un virus |
| NL8403163A NL8403163A (nl) | 1983-10-17 | 1984-10-16 | Werkwijze voor het remmen van virus voortplanting, en een anti-viraal agents. |
| DE19843437852 DE3437852A1 (de) | 1983-10-17 | 1984-10-16 | Oligodeoxynucleotide und polydeoxynucleotide, die mit einem bereich einer bei der virusvermehrung synthetisierten mrna hybridisieren und ihre anwendung als therapeutische wirkstoffe |
| BE0/213837A BE900827A (fr) | 1983-10-17 | 1984-10-16 | Procede pour inhiber la propagation de virus et agent antiviral. |
| CH4975/84A CH667593A5 (de) | 1983-10-17 | 1984-10-17 | Arzneimittel zur behandlung von virusinfektionen enthaltend oligodeoxynucleotide und/oder polydeoxynucleotide. |
| DZ847306A DZ691A1 (fr) | 1983-10-17 | 1984-10-17 | Nouveaux oligodésoxynucléotides et polydésoxynucléotides utiles. |
| FR8415930A FR2553420B1 (fr) | 1983-10-17 | 1984-10-17 | Nouveaux oligodesoxynucleotides et polydesoxynucleotides utiles comme agents antiviraux |
| IE2668/84A IE57987B1 (en) | 1983-10-17 | 1984-10-17 | Method for inhibiting viral propagation and anti-viral agent |
| MT957A MTP957B (en) | 1983-10-17 | 1984-12-12 | Method for inhibiting viral propagation and anti-viral agent |
| SG310/88A SG31088G (en) | 1983-10-17 | 1988-05-19 | Method for inhibiting viral propagation and anti-viral agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59049321A JPS60193922A (ja) | 1984-03-16 | 1984-03-16 | 抗ウイルス剤 |
| MT957A MTP957B (en) | 1983-10-17 | 1984-12-12 | Method for inhibiting viral propagation and anti-viral agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP07540396A Division JP3328682B2 (ja) | 1996-03-06 | 1996-03-06 | ヘルペスウィルスの増殖阻害方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60193922A JPS60193922A (ja) | 1985-10-02 |
| JPH0456804B2 true JPH0456804B2 (ko) | 1992-09-09 |
Family
ID=26389704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59049321A Granted JPS60193922A (ja) | 1983-10-17 | 1984-03-16 | 抗ウイルス剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60193922A (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2568254B1 (fr) * | 1984-07-25 | 1988-04-29 | Centre Nat Rech Scient | Application d'oligonucleotides lies a un agent intercalant, notamment a titre de medicament |
-
1984
- 1984-03-16 JP JP59049321A patent/JPS60193922A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60193922A (ja) | 1985-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4689320A (en) | Method for inhibiting propagation of virus and anti-viral agent | |
| KR970005274B1 (ko) | 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보스트레인(ann arbor strain) h2n2의 억제 | |
| AU708535B2 (en) | RNase L activators and antisense oligonucleotides effective to treat RSV infections | |
| US6214805B1 (en) | RNase L activators and antisense oligonucleotides effective to treat RSV infections | |
| CA2081777A1 (en) | Inhibition of influenza virus replication by oligonucleotides | |
| JPH10510435A (ja) | Ｂ型肝炎ウイルス複製のアンチセンス阻害 | |
| IL217228A (en) | Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds | |
| WO1996032474A1 (en) | Cooperative oligonucleotides | |
| GB2273932A (en) | Stable oligonucleotides | |
| JP2010068809A (ja) | Ｈｉｖ逆転写酵素により取り込まれ、そして不正確な塩基対合を引き起こすヌクレオシドアナログについてスクリーニングする方法 | |
| JP2012515165A (ja) | 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 | |
| JPH06505401A (ja) | ウイルス、特に病原性レトロウイルスによって誘発される疾病の予防または治療のための形質転換された細胞 | |
| JPH0456804B2 (ko) | ||
| JPH04352724A (ja) | 免疫調節型治療剤 | |
| JP3328682B2 (ja) | ヘルペスウィルスの増殖阻害方法 | |
| JPH0769899A (ja) | 抗ウイルス剤 | |
| CA2211877A1 (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
| WO1997044492A1 (en) | Treatment of hiv infection by interfering with host topoisomerase interaction with hiv gag and rt | |
| CA2178811A1 (en) | Anti-hepatitis b viral oligonucleotides | |
| JPH0514684B2 (ko) | ||
| KR100285586B1 (ko) | 5-하드록시메틸-2-푸르푸랄을 함유하는 비형 간염 치료제 | |
| JPS6083582A (ja) | ウイルス増殖阻害方法 | |
| JPH09227384A (ja) | 抗ｈｉｖ剤 | |
| JP2003527419A (ja) | 抗ｈｉｖ活性を有する化合物 | |
| CN115725607A (zh) | 一种鼻疽诺卡菌的致病靶基因及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |